Prajakta Badri

6PUBLICATIONS
14CO-AUTHORS
Gene and molecular therapyPollution and contamination not elsewhere classifiedNanotoxicology, health and safetyRespiratory diseasesMolecular medicine
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|May 27, 2026
Vutrisiran-Mediated Knockdown of Transthyretin in Patients with ATTR Amyloidosis.

|Dec 13, 2025
Platform Assessment of Concentration-QTc Relationship Across GalNAc-siRNA Molecules.

Prajakta Badri, Kiranmai Kolachana, Anh Duong

|Aug 28, 2023
Pharmacokinetics and Pharmacodynamics of Patisiran in Patients with hATTR Amyloidosis and with Polyneuropathy After Liver Transplantation.

Prajakta Badri, Bahru Habtemariam, Megan Melch

|Jul 25, 2022
Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial.

David Adams, Ivailo L Tournev, Mark S Taylor

|May 17, 2022
Correction to: Pharmacokinetic and Pharmacodynamic Properties of Cemdisiran, an RNAi Therapeutic Targeting Complement Component 5, in Healthy Subjects and Patients with Paroxysmal Nocturnal Hemoglobinuria.

Prajakta Badri, Xuemin Jiang, Anna Borodovsky

|Oct 13, 2020
Pharmacokinetic and Pharmacodynamic Properties of Cemdisiran, an RNAi Therapeutic Targeting Complement Component 5, in Healthy Subjects and Patients with Paroxysmal Nocturnal Hemoglobinuria.

Prajakta Badri, Xuemin Jiang, Anna Borodovsky

Pageof 1

Frequent Collaborators

2 joint publications

Julian D Gillmore

1 joint publications

David Adams

1 joint publications

Mark S Taylor

1 joint publications

Violaine Planté-Bordeneuve